Revenue Generation

Thought leaders will be introduced to the superior results using ProstaGene™, to inform use at the physician and payer level.

Promoted by CEO Richard Pestell, MD, a thought leader in Oncology Research and clinical care.

As a Laboratory Developed Tests (LDTs) the ProstaGene™ test is intended to be reimbursed at a rate of ~$3,500 with Cost of Goods (COGs) of ~$350.

Active surveillance increases the number of tests by 47% relative to new cases.

It is intended that with regulatory and reimbursement approvals, the CCR5 & Cav1 tests will be reimbursed at a rate of ~$1,897 with COGS of ~$150.

Capturing 10% of the Prostate testing market share may generate gross profits in excess of $100MM.

Upon receiving LDT & CE (European Conformity) for CCR5 & Cav-1 respectively, which addresses multiple cancers.